Islet alpha cell number is maintained in microencapsulated islet transplantation

Area of Science:

• Endocrinology
• Transplantation Biology
• Cell Biology

Background:

• Islet transplantation is a potential therapy for Type 1 diabetes, aiming to reverse hyperglycemia.
• Grafted islets often suffer from beta cell loss and diminished glucagon secretion.
• Alpha cell loss in grafts is hypothesized to result from direct contact with the implantation site.

Purpose of the Study:

• To investigate the effect of microencapsulation on islet cell survival and function post-transplantation.
• To determine if microencapsulation can prevent alpha cell loss observed in non-encapsulated islet grafts.

Main Methods:

• Utilizing microencapsulation to isolate transplanted islets from direct host tissue contact.
• Quantifying insulin- and glucagon-producing cells within microencapsulated grafts post-transplantation.
• Assessing DNA, insulin, and glucagon content of the transplanted microencapsulated islets.

Main Results:

• Microencapsulated islets showed a decrease in insulin-positive beta cells but a maintained or increased number of glucagon-positive alpha cells.
• A reduction in overall islet DNA content and insulin content was observed, indicating cell loss.
• Glucagon content remained stable, suggesting alpha cell function was preserved.
• In contrast to non-encapsulated grafts, alpha cell numbers were maintained within microencapsulated islets.

Conclusions:

• Microencapsulation appears to protect alpha cells from the loss typically seen in islet transplantation.
• Beta cell mass diminishes in microencapsulated grafts, but alpha cell integrity is preserved.
• This approach offers a potential strategy to improve the long-term efficacy of islet transplantation for diabetes.